Publications by authors named "S Marce"
Article Synopsis
- e13a2 and e14a2 are the most common transcript types of the fusion gene in chronic myeloid leukemia (CML), influencing treatment outcomes.
- The study found that patients who received at least 119 months of imatinib (IM) treatment had lower relapse rates after stopping treatment and that those with the e14a2 transcript type had better treatment-free remission (TFR) outcomes.
- While transcript type did not impact the response to second-generation tyrosine kinase inhibitors (2G-TKI), 2G-TKI treatment was linked to improved and quicker deep molecular responses for patients with the e14a2 transcript.
Flow cytometry to detect bone marrow involvement by follicular lymphoma.
Cytometry B Clin Cytom
November 2022
Article Synopsis
- High-quality data on bone marrow involvement (BMI) in follicular lymphoma (FL) is scarce, which prompted researchers to develop a new flow cytometry protocol using a 10-color tube to evaluate BMI.
- Out of 52 patients studied, 67% showed BMI through flow cytometry, with a median involvement of 1.2% leukocytes, though some discrepancies were noted when compared to the gold standard of histopathology and IGH gene rearrangement.
- The study found significant heterogeneity in immunophenotypes of FL, indicating variation among patients, but overall, the new protocol effectively detected most cases of BMI in FL.
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR.
View Article and Find Full Text PDFThe most frequent -p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that transcript types confer different responses to IM.
View Article and Find Full Text PDF